Species differences in metabolism of ripasudil (K-115) are attributed to aldehyde oxidase

References

• Acheampong AA, Chien DS, Lam S, et al. (1996). Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 26:1035–55
   PubMed Web of Science ®Google Scholar
• Akabane T, Tanaka K, Irie M, et al. (2011). Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41:372–84
   PubMed Web of Science ®Google Scholar
• Akabane T, Gerst N, Naritomi Y, et al. (2012). A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes. Drug Metab Pharmacokinet 27:181–91
   PubMed Web of Science ®Google Scholar
• Bahrami H. (2006). Causal inference in primary open angle glaucoma: specific discussion on intraocular pressure. Ophthalmic Epidemiol 13:283–9
   PubMed Web of Science ®Google Scholar
• Beedham C. (1985). Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 16:119–56
   PubMed Web of Science ®Google Scholar
• Beedham C. (1987). Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog Med Chem 24:85–127
   PubMedGoogle Scholar
• Beedham C, Miceli JJ, Obach RS. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23:229–32
   PubMed Web of Science ®Google Scholar
• Diamond S, Boer J, Maduskuie TP Jr, et al. (2010). Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277–85
   PubMed Web of Science ®Google Scholar
• Dittrich CH, Greim G, Borner M, et al. (2002). Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38:1072–80
   PubMed Web of Science ®Google Scholar
• Edeki TI, He H, Wood AJ. (1995). Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 274:1611–13
   PubMed Web of Science ®Google Scholar
• Garattini E, Fratelli M, Terao M. (2008). Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 65:1019–48
   PubMed Web of Science ®Google Scholar
• Garattini E, Terao M. (2012). The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487–503
   PubMed Web of Science ®Google Scholar
• Hall A. (2005). Rho GTPases and the control of cell behaviour. Biochem Soc Trans 33:891–5
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Yang YS, Albaugh D, et al. (2012). Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos 40:267–75
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Yang YS, Brown C, et al. (2014). Aldehyde oxidase activity in donor-matched fresh and cryopreserved human hepatocytes and assessment of variability in 75 donors. Drug Metab Dispos 42:1090–7
   PubMed Web of Science ®Google Scholar
• Imaoka S, Yamada T, Hiroi T, et al. (1996). Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51:1041–50
   PubMed Web of Science ®Google Scholar
• Inoue T, Tanihara H. (2013). Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res 37:1–12
   PubMed Web of Science ®Google Scholar
• Isobe T, Mizuno K, Kaneko Y, et al. (2014). Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res 39:813–22
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamamura M, Takasaki W, et al. (2006). Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharm Drug Dispos 27:133–9
   PubMed Web of Science ®Google Scholar
• Johns DG. (1967). Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 46:1492–505
   PubMed Web of Science ®Google Scholar
• Kitamura S, Sugihara K, Nakatani K, et al. (1999). Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 48:607–11
   PubMed Web of Science ®Google Scholar
• Kitamura S, Sugihara K, Ohta S. (2006). Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83–98
   PubMed Web of Science ®Google Scholar
• Kurosaki M, Demontis S, Barzago MM, et al. (1999). Molecular cloning of the cDNA coding for mouse aldehyde oxidase: tissue distribution and regulation in vivo by testosterone. Biochem J 341:71–80
   PubMed Web of Science ®Google Scholar
• Kurosaki M, Bolis M, Fratelli M, et al. (2013). Structure and evolution of vertebrate aldehyde oxidases: from gene duplication to gene suppression. Cell Mol Life Sci 70:1807–30
   PubMed Web of Science ®Google Scholar
• Lake BG, Ball SE, Kao J, et al. (2002). Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 32:835–47
   PubMed Web of Science ®Google Scholar
• Massey V, Komai H, Palmer G, Elion GB. (1970). On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem 245:2837–44
   PubMed Web of Science ®Google Scholar
• Moriwaki Y, Yamamoto T, Takahashi S, et al. (2001). Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. Histol Histopathol 16:745–53
   PubMed Web of Science ®Google Scholar
• Moriyasu A, Sugihara K, Nakatani K, et al. (2006). In vivo–in vitro relationship of methotrexate 7-hydroxylation by aldehyde oxidase in four different strain rats. Drug Metab Pharmacokinet 21:485–91
   PubMed Web of Science ®Google Scholar
• Nakashima M, Uematsu T, Kanemaru M. (1992). Phase I study of AT-877 (fasudil hydrochloride) in healthy subjects. Single and multiple administration. Jpn Pharmacol Ther 20:S1559–85
   Google Scholar
• Nishimura M, Naito S. (2006). Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357–74
   PubMed Web of Science ®Google Scholar
• Obach RS. (2004a). Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89–97
   PubMed Web of Science ®Google Scholar
• Obach RS, Huynh P, Allen MC, Beedham C. (2004b). Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7–19
   PubMed Web of Science ®Google Scholar
• Olson MF. (2008). Applications for ROCK kinase inhibition. Curr Opin Cell Biol 20:242–8
   PubMed Web of Science ®Google Scholar
• Pryde DC, Dalvie D, Hu Q, et al. (2010). Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441–60
   PubMed Web of Science ®Google Scholar
• Rao VP, Epstein DL. (2007). Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Biodrugs 21:167–77
   PubMed Web of Science ®Google Scholar
• Riento K, Ridley AJ. (2003). Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4:446–56
   PubMed Web of Science ®Google Scholar
• Sahi J, Khan KK, Black CB. (2008). Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Drug Metab Lett 2:176–83
   PubMedGoogle Scholar
• Shimokawa H, Takeshita A. (2005). Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25:1767–75
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. (2013a). Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol 131:1288–95
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. (2013b). Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 156:731–6
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. (2015a). Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol 133:755–61
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. (2015b). One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. [Epub head of print]. doi: 10.1111/aos.12829
   Web of Science ®Google Scholar
• Zhang X, Liu HH, Weller P, et al. (2011). In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 11:15–24
   PubMed Web of Science ®Google Scholar
• Zientek M, Jiang Y, Youdim K, Obach RS. (2010). In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322–7
   PubMed Web of Science ®Google Scholar